Moomoo AI 已提取核心訊息
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 50,000 shares of the company's common stock. The transaction, scheduled for January 29, 2024, is valued at approximately $3,025,570. The shares to be sold were acquired on the same day through the exercise of stock options, with the securities originating from the issuer and purchased with cash. This sale follows a previous transaction in the past three months where Kulkarni sold 20,000 shares, garnering total gross proceeds of $1,250,056.
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 50,000 shares of the company's common stock. The transaction, scheduled for January 29, 2024, is valued at approximately $3,025,570. The shares to be sold were acquired on the same day through the exercise of stock options, with the securities originating from the issuer and purchased with cash. This sale follows a previous transaction in the past three months where Kulkarni sold 20,000 shares, garnering total gross proceeds of $1,250,056.
同時擔任高管兼董事的CRISPR Therapeutics高管薩瑪斯·庫爾卡尼將出售該公司的5萬股普通股。該交易定於2024年1月29日進行，價值約爲3,025,570美元。擬出售的股票在同一天通過行使股票期權收購，證券來自發行人並以現金購買。此次出售是在過去三個月中進行的一筆交易之後進行的，當時庫爾卡尼出售了20,000股股票，總收益爲1,250,056美元。
同時擔任高管兼董事的CRISPR Therapeutics高管薩瑪斯·庫爾卡尼將出售該公司的5萬股普通股。該交易定於2024年1月29日進行，價值約爲3,025,570美元。擬出售的股票在同一天通過行使股票期權收購，證券來自發行人並以現金購買。此次出售是在過去三個月中進行的一筆交易之後進行的，當時庫爾卡尼出售了20,000股股票，總收益爲1,250,056美元。
有用
沒用